A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

Trial Profile

A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients With Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 02 Aug 2017

At a glance

  • Drugs CMB 305 (Primary) ; Atezolizumab
  • Indications Liposarcoma; Soft tissue sarcoma; Synovial sarcoma
  • Focus Therapeutic Use
  • Sponsors Immune Design
  • Most Recent Events

    • 02 Aug 2017 According to an Immune Design media release, early data from the study will be presented at the European Society for Medical Oncology 2017 Congress (ESMO).
    • 10 Jun 2017 Biomarkers information updated
    • 17 May 2017 According to an Immune Design media release, the company intends to submit early data from a pre-specified analysis of this study for presentation at the European Society for Medical Oncology 2017 Congress.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top